On Dec. 19, 2025, Mangoceuticals, Inc. (NASDAQ: MGRX) revealed the completion of its registered direct offering and private placement with institutional investors. The Company distributed Common Stock, pre-funded warrants, and investor warrants in the offerings, generating about $2.5 million in total gross proceeds. The transactions took place under Nasdaq rules and concluded on the same day. Mangoceuticals specializes in health and wellness products sold through the MangoRx and PeachesRx brands on a secure telemedicine platform.